Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents by Risitano, Antonio M & Rotoli, Bruno
© 2008 Dove Medical Press Limited.   All rights reserved
Biologics: Targets & Therapy 2008:2(2) 205–222 205
REVIEW
Paroxysmal nocturnal hemoglobinuria: 
pathophysiology, natural history and treatment 
options in the era of biological agents
Antonio M Risitano
Bruno Rotoli
Hematology, Department of 
Biochemistry and Medical 
Biotechnologies, Federico II 
University of Naples, Italy
Correspondence:   Antonio M Risitano
Hematology, DBBM, Federico II University 
of Naples, Via Pansini 5-80131 Naples, 
Italy
Tel +39 081 746 2037
Fax +39 081 746 2165
Email amrisita@unina.it
Abstract: Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal non-malignant hematological 
disease characterized by the expansion of hematopoietic stem cells (HSCs) and progeny mature 
cells, whose surfaces lack all the proteins linked through the glycosyl-phosphatidyl inositol 
anchor. This defect arises from an acquired somatic mutation in the X-linked phosphatidyl-
inositol glycan class A gene, with subsequent clonal expansion of the mutated HSCs as a result 
of a concomitant, likely immune-mediated, selective pressure. The disease is characterized 
by complement-mediated chronic intravascular hemolysis, resulting in hemolytic anemia and 
hemosiderinuria; capricious exacerbations lead to recurrent gross hemoglobinuria. Additional 
cardinal manifestations of PNH are a variable degree of bone marrow failure and an intrinsic 
propensity to thromboembolic events. The disease is markedly invalidating, with chronic 
symptoms requiring supportive therapy − usually including periodical transfusions; possible 
life-threatening complications may also ensue. The biology of PNH has been progressively 
elucidated in the past few years, but therapeutic strategies remained unsatisfactory for decades, 
the only exception being stem cell transplantation, which is restricted to selected patients and 
retains signiﬁ  cant morbidity and mortality. Recently, a biological agent to treat PNH has been 
developed − the terminal complement inhibitor eculizumab − which has been tested in a num-
ber of clinical trials, with exciting results. All the data from worldwide clinical trials conﬁ  rm 
that eculizumab radically modiﬁ  es the symptoms, the biology, and the natural history of PNH, 
strongly improving the quality of life of PNH patients.
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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH), ﬁ  rst described in the 18th century, is 
characterized by the typical clinical triad of hemolytic anemia, bone marrow failure, 
and propensity to thromboembolism (Rotoli and Luzzatto 1989; Dunn et al 2000; 
Rotoli et al 2006; Hill et al 2007a). It is a rare disease, with a worldwide prevalence 
estimated in the range of 1–5 cases per million (Rosse 1996) regardless of ethnicity; an 
increased prevalence is reported in some regions which also harbor higher incidence 
of aplastic anemia (eg, Thailand and some other Asian countries) (Pramoonjago et al 
1999). While the original denomination focused on a single component of the disease − 
namely intravascular hemolysis and subsequent hemoglobinuria − its complexity 
emerged in subsequent studies, and remained a riddle for generations of investigators. 
In the past 3 decades most pathogenic mechanisms have been unraveled, although 
some biological aspects have not been elucidated yet.
PNH is a hemolytic anemia resulting from the clonal expansion of one or a few 
abnormal hematopoietic stem cells (HSCs) (Oni et al 1970). This defect was identiﬁ  ed 
by genetic studies in the 1990s as a mutation in the X-linked phosphatidyl-inositol Biologics: Targets & Therapy 2008:2(2) 206
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glycan class A (PIG-A) gene (Takeda et al 1993; Luzzatto 
et al 1997). PNH is therefore an acquired genetic blood 
disorder; however, the PIG-A mutation is likely insufﬁ  cient 
to cause the disease and additional events may be involved 
(Rotoli and Luzzatto 1989), as noted below. Indeed, the 
genetic abnormality does not explain the entire clinical phe-
notype of PNH, especially marrow failure and thrombosis. 
Here we will review the natural history of PNH, focusing 
on clinical manifestations and their speciﬁ  c pathogenic 
mechanisms, aiming to give a theoretical background for 
targeted therapeutic strategies. In addition, we will discuss 
the clinical results from recent international trials using the 
complement inhibitor eculizumab (Soliris®) as treatment for 
PNH patients.
Pathophysiology
As mentioned above, PNH has a well-recognized genetic 
cause that is neither inherited nor transmitted to the prog-
eny (Takeda et al 1993; Luzzatto et al 1997). It develops 
through a somatic mutation in the PIG-A gene occurring in 
HSC(s), which originate progeny mature blood cells with 
the bizarre feature of a lack of several proteins from their 
surface. This abnormality was ﬁ  rst described in the 1980s 
(Nicholson-Weller et al 1983; Selvaraj et al 1988), and rap-
idly became the hallmark of PNH, although its relationship 
with the pathophysiology of the disease remained obscure 
at that time. Subsequently, it became clear that all the pro-
teins missing from the PNH cell surface share a common 
mechanism for attaching to the cell membrane, which was 
identiﬁ  ed in a speciﬁ  c glycolipid structure named glycosyl-
phosphatidyl inositol (GPI) anchor (Mahoney et al 1992). In 
1993, using complementation of GPI-anchored protein deﬁ  -
cient cell lines and expression cloning, Kinoshita and col-
leagues ﬁ  rst isolated the cDNA of the PIG-A gene (Takeda 
et al 1993; Miyata et al 1993). PIG-A is a housekeeping gene 
located on the short arm of the X chromosome (Xp22.1); 
the organization of the genomic gene was described in 1994 
(Bessler et al 1994). The PIG-A gene encodes an enzyme 
essential, in combination with at least two other proteins, to 
transfer N-acetyl glucosamine to phosphatidyl inositol; this 
is the very ﬁ  rst step of the glycosyl-phosphatidyl inositol 
(GPI)-anchor biosynthesis (Hirose et al 1992; Takahashi 
et al 1993). All mutations identiﬁ  ed in PNH patients affect 
the PIG-A gene; no abnormalities were found in any of the 
other numerous genes involved in the subsequent metabolic 
steps of the GPI-anchor synthesis. In fact, PIG-A is the 
only X-linked gene, and a single mutational event is suf-
ﬁ  cient to impair GPI-anchor biosynthesis (also in females, 
as a result of X-chromosome functional inactivation). 
As an exception, an autosomal recessive inherited GPI 
deﬁ  ciency resulting from a mutation of the PIG-M gene 
has been recently described in two kindreds; however, the 
phenotype was clearly different from that of PNH, with 
a partial GPI deﬁ  ciency resulting in a clinical syndrome 
characterized by propensity to thrombosis and seizures, in 
the absence of signiﬁ  cant hemolysis (Almeida et al 2006; 
Almeida et al 2007).
The role of the GPI-anchor in cell biology seems to be 
very important, as supported by its high conservation in 
eukaryotic cells, including yeast and trypanosome; however, 
the functional implications of the GPI-anchoring of proteins, 
and of the GPI-anchor itself, are not completely understood. 
It is known that GPI-anchored proteins (GPI-APs) are not 
randomly distributed on the cell surface, but rather constitute 
membrane subdomains enriched in speciﬁ  c lipids, such as 
cholesterol and sphyngolipids; these structures, called rafts, 
seem to be involved in membrane trafﬁ  cking and remodel-
ing, including capping and endo-, exo-, and potocytosis, as 
well as in signal transduction (eg, immunological synapse) 
(Goebel et al 2002).
As a result of the GPI-anchor deﬁ  ciency, PNH cells 
lack all GPI-APs on their surface (Figure 1A); so far, 
more than 25 different proteins sharing the GPI-anchor-
ing system have been described on blood cells (Table 1) 
(Rotoli et al 1993), their speciﬁ  c functions being only 
partially known. However, some GPI-APs are function-
ally well-described proteins, and have been essential to 
fully unravel the pathogenic mechanisms of some clinical 
manifestations of PNH (Figure 2). In fact, among the GPI-
APs there are two complement-regulatory proteins, namely 
CD59/MIRL (Membrane Inhibitor of Reactive Lysis) 
(Zalman et al 1987; Okada et al 1990) and CD55/DAF 
(Decay Accelerating Factor) (Nicholson-Weller et al 1983; 
Nicholson-Weller et al 1985). They act at different levels 
of the complement cascade (Figure 3): CD55 controls early 
complement activation, inhibiting C3 and C5 convertases 
(Burge et al 1981; Medof et al 1984), while CD59 inter-
feres with the terminal effector complement, blocking the 
incorporation of C9 onto the C5b-C8 complex, forming the 
membrane attack complex (MAC) (Shin et al 1986; Zalman 
et al 1986). The deﬁ  ciency of such proteins leads to the 
increased susceptibility of PNH red blood cells (RBCs) 
to complement mediated lysis, resulting in the typical 
intravascular hemolysis (Holguin et al 1989). In addition, 
hypersensitivity to complement activation in vitro leads 
to red cell destruction upon serum acidiﬁ  cation, a feature Biologics: Targets & Therapy 2008:2(2) 207
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utilized as a diagnostic assay for PNH for several decades 
(the HAM test, recently replaced by ﬂ  ow cytometry). A low 
level of complement activation is a constant physiological 
phenomenon greatly ampliﬁ  ed during inﬂ  ammatory or 
infectious diseases; thus, PNH erythrocytes chronically 
undergo intravascular hemolysis in PNH patients due to 
CD55 and CD59 deﬁ  ciency, with a lifespan reduced to 10% 
compared with that of normal RBCs (Wiedmer et al 1993). 
GPI-AP deﬁ  ciency on RBCs may be complete (PNH type 
III cells) or partial (PNH type II cells), resulting in differ-
ent sensitivity to complement mediated lysis, as initially 
described by Rosse (Rosse and Dacie 1966; Rosse 1990). 
However, particular aspects of hemolysis in PNH are still 
debated; for instance, it is still unclear why exacerbations 
occur mainly during the night. In a functional hierarchy, 
CD59 was demonstrated as playing a major role (Wilcox 
et al 1991). This is also supported by the observation of rare 
patients harboring inherited deﬁ  ciency of a single molecule 
(Yamashina et al 1990; Shichishima et al 1999); in fact, 
a unique CD59-deﬁ  cient patient had a PNH-like picture, 
whereas subjects deﬁ  cient in CD55 on red cell membrane 
(ie, those carrying the rare Inab blood group phenotype) 
showed no clinically signiﬁ  cant hemolysis.
CD55 and CD59 are deﬁ  cient on RBCs, but also on 
white blood cells (WBCs) and platelets (Nicholson-Weller 
et al 1985); however, as far as WBCs are concerned, there 
is no evidence of reduced leukocyte lifespan in PNH 
patients, probably because nucleated cells have an additional 
transmembrane (ie, non GPI-linked) complement inhibitor 
(CD46) (Christmas et al 2006). In contrast, uncontrolled 
complement activation on platelets has been hypothesized as 
a possible explanation for another clinical hallmark of PNH, 
namely the propensity to thromboembolic events (Figure 2). 
In fact, complement activation might lead to platelet activa-
tion and aggregation, enhancing clot formation; however, no 
demonstration of such a mechanism has been provided up to 
now, and other different mechanisms have been postulated. In 
PNH, microvesicles are known to be released upon hemolysis 
and complement activation from RBCs (Hugel et al 1999), 
WBCs (monocytes) and platelets (Wiedmer et al 1993; Simak 
et al 2004), and even from the endothelium; their procoagu-
lant action is commonly accepted, but their speciﬁ  c role in the 
pathophysiology of thromboembolisms in PNH still needs to 
be documented. An additional mechanism of thrombophilia 
in PNH might be the impairment of the ﬁ  brinolytic system, 
due to the lack of membrane-bound urokinase-type plas-
minogen activator receptor (uPAR), which is GPI-linked, 
and to the excess of its soluble form (Ninomiya et al 1997; 
Sloand et al 2006). Finally, thrombophilia in PNH may arise 
from the build-up of cell-free plasma hemoglobin due to 
hemolysis (Olsen et al 1996; Schafer et al 2004). This may 
occur through ability of free hemoglobin to scavenge nitric 
oxide from plasma, blocking its inhibitory action on platelet 
aggregation and ahesion to vascular endothelium (Rother 
et al 2005). Obviously, additional acquired or inherited risk 
factors may increase individual predisposition to thrombosis; 
genetically, the Factor V Leiden mutation and the 677 CT 
methylenetetrahydrofolate reductase gene variant (as well as 
MTHFR polymorphisms leading to hyperhomocysteinemia) 
may have a relevant role, although this has not been proven 
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Figure 1 Paroxysmal nocturnal hemoglobinuria (PNH) pathophysiology.   A. PIG-A 
mutations: mutation occurring in the PIG-A gene may affect the synthesis or the function 
of the encoded protein, resulting in the impairment of the ﬁ  rst step of GPI-anchor 
biosynthesis. As a result, all proteins linked to the cellular membrane through this 
mechanism are lacking from the surface. B. The dual pathophysiology theory: PIG-A 
gene mutation may occur without provoking the PNH disease. To induce the clonal 
expansion necessary for developing clinical PNH, additional factors should occur, which 
create conditions permissive to expansion of mutated cells. Such extrinsic factors are 
postulated similar to those inducing stem cell exhaustion in aplastic anemia, which 
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Looking at PNH biology in depth, we have discussed 
the original molecular defect in HSCs and some subsequent 
functional abnormalities of the progeny blood cells leading 
to speciﬁ  c clinical manifestations; however, what is the miss-
ing link and, likely, the true mystery of PNH is the reason 
for the expansion of GPI-deﬁ  cient clones within the context 
of a bone marrow failure syndrome. Of note, hematopoiesis 
in PNH is a mosaicism of phenotypically normal HSCs and 
PIG-A mutated HSCs; in addition, regardless of the genetic 
defect, hematopoiesis is impaired in almost all PNH patients, 
even in the presence of a broad clinical heterogeneity (Rotoli 
et al 1982; Maciejewski et al 1997). As mentioned above, 
PNH is a true disease of the HSC, as marked by the PIG-A 
mutation; however, the HSC defect does not entirely explain 
the phenotype. In fact, a series of observations suggest that 
the PIG-A mutation is necessary but not sufﬁ  cient per se to 
cause the disease:
(i)  A few (10–50 cells per million) circulating granulocytes 
harboring the PNH phenotype may be demonstrated 
also in healthy individuals by ﬂ  ow cytometry, and their 
speciﬁ  c PIG-A mutation may be identiﬁ  ed by a nested 
PCR technique (Araten et al 1999; Hu et al 2005).
(ii) GPI-AP deficient lymphocytes were detected in 
lymphoma patients shortly after treatment with alem-
tuzumab (a monoclonal antibody that recognizes the 
GPI-AP CD52), and progressively disappeared after 
treatment withdrawal (Hertestein et al 2005).
(iii)   The expansion of the aberrant PNH clone seen in PNH 
patients could not be reproduced in several murine mod-
els developed with the aim of creating the disease (Rosti 
et al 1997; Jasinski et al 2001; Keller et al 2001), even 
when embryonic stem cells were employed. Thus, at 
least in these models, the PNH clone does not seem to have 
any intrinsic proliferative advantage to overcome normal 
hematopoiesis (Jasinski et al 2001; Keller et al 2001); 
this is also conﬁ  rmed by several data on in vitro growth 
of patient-derived PNH and wild-type hematopoietic 
progenitors (Young and Maciejewski 2000).
(iv)   PNH hematopoiesis is certainly clonal, but not neces-
sarily monoclonal. In fact, PNH hematopoiesis may in 
Table 1 Glycosyl-phosphatidyl inositol (GPI)-linked proteins on blood cells and their function
Antigen Alternative  denomination  Function
CD14  LPS-LPB-r  Monocyte adhesion and activation
CD16 FcγR-IIIb Low  afﬁ  nity receptor for IgG
CD24   Ca2+ ﬂ  ux, triggers H2O2 production by PMN
CD48  BLAST-1  Counter-receptor for CD2
CD52  Target of Campath-1  Unknown
CD55  DAF  Accelerates C3 and C5 convertase decay, Cromer antigen
CD58  LFA-3  Counter-receptor for CD2
CD59  MIRL  Binds C8/C9, thus inhibiting MAC assembly
CD66b  CGM6 (CEA family member)  Granulocyte adhesion/activation
CD66c NCA  Granulocyte  adhesion/activation
CD73  5’-NT  Purine/pyrimidine ribo/deoxyribonucleoside phosphorilation
CD87 uPAR  Urokinase  receptor
CD90 Thy-1  analog  Adhesion
CD108   Unknown 
CD109  Platelet Gove/b alloantigen  Unknown
CD157  BST-1  enzyme; adhesion/signalling (CD38 family)
ACHE  Red cell acetylcholinesterase  Enzyme, unknown substrate on RBC
NAP  Neutrophil alkaline phosphatase  Enzyme, granulocyte function
PrPc  Cellular prion protein  Unknown
TRAIL R-3  Trail receptor III; DcR-1  Decoy receptor for TRAIL
ULBPs  UL-16 binding proteins  Activating ligand for NKG2D/DAP10 receptor
PRV-1  Polycythemia rubra vera 1  Unknown
NB1/NB2   Neutrophil  antigen 
JMH  John Milton Hagen antigen  Red cell antigen
Holley Gregory    Red cell antigen 
Dombrock    Red cell antigen 
YT    Red cell antigen 
Platelet GP500    Platelet antigen 
Platelet GP175    Platelet antigen 
Abbreviations: MAC, membrane attack complex; PMN, polymorphonuclear leukocytes; RBC, red blood cells.Biologics: Targets & Therapy 2008:2(2) 209
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some cases be oligo- rather than monoclonal, as initially 
supported by differential susceptibility to complement 
lysis (Rosse et al 1966), subsequently by ﬂ  ow cytom-
etry (van der Schoot et al 1990), and ﬁ  nally conﬁ  rmed 
by PIG-A sequencing (Endo et al 1996); this observa-
tion raised the question of whether the expansion of 
more clones carrying the same functional defect, but 
molecularly heterogeneous, is compatible with a ran-
dom process, or rather may result from not stochastic 
processes, such as selection. The latter hypothesis may 
be supported by the observation that relapse of PNH 
may be sustained by clones harboring PIG-A mutations 
which are different from those identiﬁ  ed at diagnosis 
(Nafa et al 1998).
According to this background, the hypothesis of a dual 
pathophysiology for PNH has been developed, also known 
as the “relative advantage” (Figure 1B) (Rotoli and Luzzatto 
1989; Luzzatto and Bessler 1996) or the “escape” theory 
(Dunn et al 2000). According to this theory, a mutation in 
the PIG-A gene might be a fairly common phenomenon, 
with no major biological consequences, because the mutated 
cell has no chance of expanding in the presence of a vast 
majority of normal cells. In fact, no intrinsic proliferative 
advantage has been demonstrated in PNH hematopoietic 
progenitors (Araten et al 2002). However, external factors 
may alter this equilibrium, creating an environment permis-
sive for the expansion of PNH clone(s), and possibly leading 
to the occurrence of a single PIG-A mutated stem cell sus-
taining hematopoiesis even for the rest of the patient’s life 
(Nishimura et al 2002). The nature of such extrinsic trigger 
may be inferred from the observation that most PNH patients 
also show evidence of bone marrow failure, and that several 
aplastic anemia (AA) patients may harbor distinct PNH 
clones. Thus, it is reasonable to hypothesize that pathogenic 
mechanisms involved in AA may also play a pivotal role in 
PNH, representing the additional factor required for devel-
oping clinical PNH once a PIG-A mutation has occurred 
(without any speciﬁ  c chronologic order).
Indeed, in acquired marrow failure syndromes HSCs are 
known to be intrinsically normal, but subject to an extrinsic 
damage affecting their hematopoietic function. In idiopathic 
AA immunological mechanisms play a pivotal role in 
damaging the hematopoietic compartment, leading to HSC 
pool consumption or functional impairment and subsequent 
pancytopenia. A wealth of experimental and clinic evidence 
supports the presence of anti-hematopoiesis immune attack, 
although the target antigens are still undeﬁ  ned, as are the 
mechanisms leading to the breach in immune tolerance. 
Unknown triggers of autoimmunity induce a cellular 
immune response resulting in a preferential expansion of 
speciﬁ  c T cell clones that may damage the hematopoietic 
Figure 2 Effect of glycosyl-phosphatidyl inositol anchored proteins (GPI-AP) deﬁ  ciency 
on blood cell populations. A. The lack of the complement regulators CD59 and CD55 
on red blood cells (RBCs) accounts for their susceptibility to complement mediated 
lysis resulting in the clinical hallmark of PNH, intravascular hemolysis. B. Deﬁ  ciency 
of complement regulators on platelets may account for their putative propensity 
to activation and aggregation, possibly leading to increased clot formation and 
thromboembolism. Thrombophilia in PNH may also be related to NO consumption 
occurring in the presence of increased free Hb resulting from hemolysis, as well as 
to the impairment of the ﬁ  brinolytic system due to the lack of membrane uPAR (see 
text). C. The lack of anchored proteins GPI-AP has been postulated as putative cause 
of the expansion of the PNH clone over normal hematopoiesis; the presence of a 
GPI-linked immune target or a more generic reduced sensitivity to immune effector 
mechanisms has been hypothesized to explain the immune escape of the PNH clone, 
but deﬁ  nitive evidence is still lacking.
Figure 3 Mechanism of hemolysis in paroxysmal nocturnal hemoglobinuria red blood 
cells (PNH RBCs). The activation of both the alternative and the classical pathways 
of the complement cascade converge on the activation of a C5 convertase; PNH 
RBCs lack CD59, which normally inhibits the assembly of membrane attack complex 
(MAC), and undergo hemolysis. In addition, the early alternative pathway is dysregu-
lated on PNH as a result of the absence of the C3 convertase inhibitor CD55; thus, 
PNH RBCs experience uncontrolled complement activation through the alternative 
pathway.   This may explain C3 accumulation on PNH RBCs when hemolysis is blocked 
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progenitors, directly or through indirect mechanisms, such 
as the production of inhibitory cytokines. Stem cell damage 
can be mediated by cytokine-transduced inhibition (mostly 
type I cytokines, such as interferon-γ and tumor necrosis 
factor-α) (Sato et al 1997; Dufour et al 2001; Sloand et al 
2002), or by direct cell-mediated killing due to cytotoxic 
lymphocytes (CTLs). Such mechanisms, which may 
attack innocent bystander cells in addition to the primary 
target cells, ultimately result in apoptosis, the main key 
mechanism of HSC damage. Circulating and marrow CTLs 
have been demonstrated in vivo in AA patients, and their 
inhibitory effect on hematopoiesis has been documented 
in vitro (Zoumbos et al 1995; Nakao et al 1997; Zeng 
et al 2001; Kook et al 2002; Risitano et al 2002; Plasilova 
et al 2003); recently, we have dissected this cellular immune 
response at the molecular level through the identiﬁ  cation 
of in vivo dominant T cell clonotypes, which are evidence 
of a pathogenic antigen-driven immune response (Risitano 
et al 2004).
In PNH, an antigen-driven immune response target-
ing the marrow tissue may be postulated, which possibly 
correlates with the selective expansion of the PIG-A mutated 
clone; in fact, if the target on HSC membrane is a GPI-
linked molecule, PNH HSC may escape this injury while 
normal HSC are killed. Evidence of immune derangement 
in PNH has been produced; as for AA, oligoclonality of the 
T cell pool has been reported (Karadimitris et al 2000), and 
immunodominant pathogenic CTL clones may be detected 
in most PNH patients (Risitano et al 2002, 2004; Plasilova 
et al 2004; Gargiulo et al 2007), sometimes phenotypically 
resembling a subclinical LGL proliferation (Risitano et al 
2005). In addition, according to a recent report, these effec-
tor T cells overexpress the activating isoforms of inhibiting 
superfamily receptors which elicit a powerful cytolytic 
activity (Poggi et al 2005).
Gene expression proﬁ  ling has been employed to inves-
tigate putative differences between normal and PNH HSCs: 
when CD34+ cells from PNH patients were separated 
according to the presence or absence of GPI-AP on their 
surface, distinct patterns of gene expression were identi-
ﬁ  ed. Phenotypically normal (GPI-AP positive) CD34+ cells 
harbored diffuse abnormalities of their transcriptome, with 
over-expression of genes involved in apoptosis and immune 
activity, paralleling the ﬁ  ndings seen in CD34+ cells of AA 
patients. By contrast, phenotypically abnormal PNH CD34+ 
(GPI-AP negative) showed a gene expression proﬁ  ling closer 
to that obtained in CD34+ cells from healthy individuals 
(Chen et al 2005). The presence of sublethal damage in 
phenotypically normal HSCs but not in their PIG-A mutated 
counterpart strongly supports the presence of an immune 
attack to the hematopoietic stem/progenitor cells that spares 
PNH cells; thus, they ultimately expand as a result of a selec-
tive pressure negatively acting on normal hematopoiesis. The 
“escape” of PNH cells may be interpreted in various man-
ners. Contradictory data have been produced on a putative 
differential sensitivity to inhibitory stimuli between normal 
and PNH cells; susceptibility to apoptosis has been reported 
to be increased, normal, or decreased in different models. 
Recently, it has been shown that human cell lines carrying the 
PIG-A mutation are less susceptible to NK-mediated killing 
compared to their normal counterpart (Nagakura et al 2002). 
In a more sophisticated model, GPI-deﬁ  cient cells were not 
able to induce primary and secondary stimulation of both 
antigen-speciﬁ  c and alloreactive T cells, providing experi-
mental support to the hypothesis that the PNH clone could 
inefﬁ  ciently interact with the immune system (Murakami 
et al 2002). However, the actual mechanisms causing the 
escape are still elusive. They may include the absence of 
speciﬁ  c GPI-APs directly targeted by effector immune cells, 
or a protection due to the absence of important molecules 
involved in cell-cell interaction (eg, accessory molecules). 
Alternatively, a broader impaired sensitivity to common 
effector mechanisms may be hypothesized, possibly due to 
the lack of GPI-APs or to non-speciﬁ  c structural changes of 
the raft structure in the outer surface.
Clinical features and natural history
Diagnosis
PNH has to be suspected in patients showing mild to severe 
anemia with moderate reticulocytosis, elevated serum lac-
tate dehydrogenase (LDH) and possibly mild jaundice, with 
negative Coombs test; all these clues suggest a non-immune 
hemolytic anemia. The occurrence of dark urine and urinary 
hemosiderin, both evidence of intravascular hemolysis, 
strongly suggest PNH. Additional signs to be considered 
are the presence of mild to severe leuco-thrombocytopenia 
and/or a history of thromboembolic events of unknown 
origin, including cerebrovascular accidents. In specific 
conditions, PNH may be considered even in the absence of 
clinically evident hemolytic anemia, such as in patients with 
AA or those showing recurrent thromboembolic events in the 
absence of documented risk factors; all these patients may 
deserve a careful screening for PNH.
Until the eighties, the diagnosis was conﬁ  rmed by the 
Ham test, which assesses the lysis of RBCs in acidiﬁ  ed serum; 
less speciﬁ  c but simpler tests were the sucrose and the sugar Biologics: Targets & Therapy 2008:2(2) 211
Paroxysmal nocturnal hemoglobinuria in the era of eculizumab
water test (both based upon lysis in serum with reduced ionic 
strength). However, at present the diagnosis of PNH is based 
on ﬂ  ow cytometry analysis of blood cells (Parker et al 2005; 
Rotoli et al 2006); the high sensitivity and speciﬁ  city of this 
analysis made the Ham and similar tests obsolete. In fact, 
ﬂ  uorochrome-conjugated monoclonal antibodies speciﬁ  c to 
several GPI-APs expressed on the various blood cell lineages 
are available for routine testing; thus, simultaneous multi-
parameter analysis allows accurate detection of GPI-AP 
deﬁ  cient populations, measuring their extent within each 
cell lineage. By this technique, one or two RBC populations 
with abnormal expression of GPI-APs may be shown in PNH 
patients: one completely lacking GPI-AP expression (type 
III PNH cells), and another characterized by GPI-AP faint 
(dim) expression (type II PNH cells). These ﬁ  ndings match 
the observation initially made by Rosse (Rosse 1990), dem-
onstrating the presence of distinct subpopulations of RBCs 
with different sensitivity to complement-mediated lysis; as 
discussed above, this may also imply that different popula-
tions may be genetically different, reﬂ  ecting the expansion 
of two or more clones (as a result of a selective pressure for 
PIG-A mutated HSCs). The ﬁ  nding of GPI-AP deﬁ  cient 
populations may be obtained for each cell lineage, even if 
discrimination between type II and type III PNH cells is 
more difﬁ  cult for white blood cells; antibodies speciﬁ  c for 
GPI-APs selectively expressed by different cell lineage may 
render the test more sensitive and speciﬁ  c. The simultane-
ous absence of different GPI-linked proteins on the same 
cells validates the speciﬁ  city of the test; using this method, 
ﬂ  ow cytometry analysis detects even very small PNH clones 
(below 1% of the tested cell population) (Alﬁ  nito et al 1996; 
Boccuni et al 2000; Richards et al 2000). More recently, the 
novel ﬂ  uorescent reagent aerolysin, which speciﬁ  cally binds 
the GPI anchor, showed even greater sensitivity, with detec-
tion limits dropping by 1–2 logs compared with standard 
ﬂ  ow cytometry (Brodsky et al 2000; Sutherland et al 2007). 
Molecular studies on DNA or mRNA, aimed to identify the 
causative speciﬁ  c mutation within the PIG-A gene, are clini-
cally unnecessary (even normal individuals may harbor a few 
PNH cells); in fact, they do not add clinically relevant data 
and may be even misleading, so they are now usually limited 
to research purposes.
Classiﬁ  cation of PNH
Recently, a group of experts has classiﬁ  ed PNH into dis-
tinct clinical entities, based on the improved information 
coming from the use of ﬂ  ow cytometry. According to this 
classiﬁ  cation (Parker et al 2005), three subgroups have been 
proposed: i. classic PNH; ii. PNH in the setting of another 
bone marrow disorder (eg, aplastic anemia, myelodysplastic 
syndrome, or myeloﬁ  brosis); iii. PNH-subclinical, in the set-
ting of another bone marrow disorder (as above). However, 
this classiﬁ  cation may be argued, and some concerns need 
to be addressed. There is overlap between classic PNH and 
PNH in the setting of another bone marrow disorder, given 
that hemolysis and some degree of bone marrow failure are 
hallmarks in both groups. Indeed, the presence of signs of 
marrow failure (ie, leukopenia, thrombocytopenia, reduced 
number of circulating and bone marrow colony forming 
cells) cannot be considered a discriminator between different 
groups of patients. In our opinion, some degree of marrow 
failure is present in all classic PNH patients, consistent 
with the pathophysiology of the disease, as described by 
the dual theory discussed above. Patients showing severe 
marrow failure may have various degrees of hemolysis, 
from the massive type as in classic PNH, to the subclini-
cal one, with all the intermediate forms; thus it is difﬁ  cult 
to identify precise cut-offs. Similarly, some degree of 
morphologic abnormalities deﬁ  nable as dysplasia, mostly 
of the erythroid lineage, may be consistent with stressed 
hematopoiesis; thus, the difference between PNH and PNH 
in the context of myelodysplastic syndromes is not clear-cut. 
Even the presence of karyotypic abnormalities may be an 
epiphenomenon resulting from clonal hematopoiesis and 
ﬁ  xation of possible mutations, rather than an indicator of 
the presence of a true myelodysplastic (preleukemic) clone 
(Araten et al 2001). Finally, PNH-subclinical refers to the 
presence of very small GPI-deﬁ  cient clones deprived of any 
clinical signiﬁ  cance; in this context, the term PNH itself is 
misleading and should not be used, since none of the clini-
cal manifestations of this condition are present. The term 
“acquired GPI-AP deﬁ  ciency” seems to be more appropriate, 
and might be extended to the entire classiﬁ  cation (possibly 
including other acquired GPI-AP deﬁ  ciency, such as those 
emerging within lymphocyte subsets after treatment by 
alemtuzumab) (Hertenstein et al 1995). In addition, this 
deﬁ  nition also better applies to the rare patients showing 
GPI-AP deﬁ  cient neutrophils and monocytes, with no PNH 
erythrocytes; such patients, who possibly reﬂ  ect a PIG-A 
mutation occurring in committed hematopoietic progenitors 
rather than in a multipotent HSC, remain often undiagnosed 
and are excluded from the proposed classiﬁ  cation.
Natural history
As recalled above, PNH is dominated by the clinical triad 
of chronic intravascular haemolytic anemia, propensity Biologics: Targets & Therapy 2008:2(2) 212
Risitano and Rotoli
to develop thromboembolic events and stigmata of bone 
marrow failure. While intravascular hemolysis is constant 
in all typical PNH patients, thrombosis and cytopenia have 
a variable prevalence within the PNH population and may 
be undetectable in single patients. This is mostly true for 
thromboembolic events, which are erratic and unpredict-
able, and may not affect all individuals, although recur-
rence is frequent after the ﬁ  rst episode (Hillmen et al 1995; 
Socie et al 1996).
Hemolysis is present in all PNH patients, but anemia 
occurs with variable severity; this results from the degree 
of complement activation and subsequent hemolysis, as 
well as from the capacity of compensatory erythropoiesis, 
which depends in turn on the efﬁ  ciency of the residual 
marrow function (indicated by reticulocyte count). Indeed, 
the size of the PNH clone within the total RBCs and the 
type of PIG-A molecular lesion accounting for the different 
sensitivity to complement-mediated lysis (ie, type II and 
type III PNH RBCs) shape the clinical picture, with some 
patients having an almost normal hemoglobin level and 
others requiring massive transfusional support. Exacerba-
tions of hemolysis are typical, and account for the term 
paroxysmal nocturnal hemoglobinuria; they are unpredict-
able in most cases, although some patients experience quite 
regular crises. Paroxysms likely reﬂ  ect transient comple-
ment activation above the physiological low-level (which 
is due to the alternative pathway), and are often associated 
with external triggers such as infections and inﬂ  ammatory 
responses, which massively activate both the classical and 
alternative complement pathways. Beside the paroxysms, 
anemia may signiﬁ  cantly vary during the clinical course 
of individual patients, with cases suddenly worsening and 
others unexpectedly improving in the absence of any known 
reason; anecdotal cases showing spontaneous remission of 
the disease have also been reported (Hillmen et al 1995; 
Socie et al 1996; Peffault de Latour et al 2006). Signs of 
intravascular hemolysis are jaundice, hemoglobinuria, 
increased LDH, and increased unconjugated bilirubinemia; 
the symptoms are those common to other types of hemolytic 
anemia, such as asthenia, fatigue to the extent of lethargy, 
with signiﬁ  cant quality of life impairment. In addition, 
some speciﬁ  c symptoms have been described, mostly in 
association with paroxysms, including dysphagia, painful 
abdominal crises and erectile dysfunction; these symptoms 
have been linked to smooth muscle dystonia possibly result-
ing from local nitric oxide (NO) deﬁ  ciency subsequent to 
NO consumption by excess free hemoglobin (Rosse 2000; 
Moyo et al 2004; Rother et al 2005). All these symptoms 
signiﬁ  cantly affect the well-being of PNH patients, even if 
they are often underestimated by physicians because they 
are not life-threatening.
Cytopenias are frequent, and may be anything from mild 
to severe, depending on the underlying bone marrow defect; 
some patients may develop true aplastic anemia during the 
course of the disease, and may require speciﬁ  c treatment. 
The consequences of cytopenia include increased risk of 
infection and hemorrhage; their management depends on the 
severity of the cytopenia and on the clinical picture, parallel-
ing that of aplastic patients. In addition, a speciﬁ  c infectious 
risk may be present as a result of impaired function of PNH 
neutrophils and monocytes, mostly affecting microorgan-
ism destruction through the radical oxygen species pathway 
(Cacciapuoti et al 2007).
Thrombosis is the most life-threatening clinical manifes-
tation. It usually affects veins, and occurs in sites unusual for 
patients with other types of thrombophilia; typical sites are 
the suprahepatic veins, leading to the Budd-Chiari syndrome, 
mesenteric veins, the splenic vein, and cerebral veins. The 
incidence of thrombosis seems to be different according 
to ethnicity, with Asian patients showing lower risk than 
Europeans or Americans, or particularly Afro-Americans and 
Hispanics (Nishimura et al 2004). Maybe this results from 
the multifactorial pathophysiology of thrombosis in PNH 
as previously discussed, and from the possible contribution 
of genetic factors predisposing to thrombosis. In various 
observations thromboses have been reported associated with 
massive intravascular hemolysis and larger WBC PNH clones 
(Hall et al 2003; Moyo et al 2004); even if this statement has 
to be conﬁ  rmed, it has to be remarked that even patients with 
small clones have a signiﬁ  cant thrombosis risk compared to 
healthy individuals (Hall et al 2003). Thromboembolic events 
may signiﬁ  cantly affect survival; as a whole, thrombosis 
may affect half of PNH patients, accounting for at least one 
third of mortality.
PNH is a clonal but non-malignant disease; even if pro-
gression to acute leukemia has been occasionally reported 
(sometimes leading to overestimation as a result of preferen-
tial reporting), it has been estimated in the range of 2%–3%, 
similar to that reported for AA patients. PNH is a very rare 
disease; information on large series are few and somewhat 
dated; however, the estimated median survival may be over 
10 years, with a quarter of patients surviving longer than 
25 years (Socié et al 1996; Hillmen et al 2005; Peffault de 
Latour 2006). These data may have a bias due to a negative 
selection of patients presenting with early complications (eg, 
those with lethal thrombosis), and do not consider changes Biologics: Targets & Therapy 2008:2(2) 213
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in the management of PNH, including transplant procedures 
and, more recently, eculizumab treatment. As discussed, the 
major causes of death are thrombosis, followed by infectious 
complications and, lastly, hemorrhage; thus, an aplastic pre-
sentation signiﬁ  cantly affects the prognosis. Notwithstanding 
the relatively long survival, the course of the disease may be 
stormy, with frequent hospitalizations, possible comorbidi-
ties, and subsequent poor quality of life.
Management: the pre-eculizumab 
era
Supportive treatment
The treatment of PNH is mainly supportive, aiming to 
control the clinical manifestations of the disease. Thus, it 
may be divided into management of hemolysis and anemia, 
management of thrombophilia, and management of bone 
marrow failure.
Management of hemolysis and anemia
Hemolysis and the subsequent anemia are the hallmarks of 
PNH, and usually require speciﬁ  c treatment. Unfortunately, 
until the new millennium there were no clinically satisfac-
tory options for controlling hemolysis. Steroids were broadly 
used as chronic administration or for acute hemolytic crises. 
Indeed, some investigators claim that steroids are useful 
in controlling chronic complement-mediated hemolysis 
(Issaragrisil et al 1987; Bourantas 1994) and, even more, 
paroxysmal crises, likely interfering with complement activa-
tion and/or underlying conditions triggering the complement 
cascade; however, so far no conclusive data or convincing 
mechanisms of action have been provided. Clinically, steroids 
seem to ameliorate patient well-being even in the absence of 
complete control of hemolysis (Parker et al 2005); in particu-
lar, they may be effective in improving symptoms associated 
with paroxysmal crises, such as dysphagia and abdominal 
pain (possibly as a result of less severe crises). However, 
since the long-term toxicity of chronic steroidal therapy, in 
the range of 0.5–1 mg/kg, advises against its systematic use 
in PNH patients, it is currently not recommended.
Androgens have been utilized, too, with limited beneﬁ  t 
(Harrington et al 1997); however, given their potential util-
ity in stimulating erythropoiesis and megakaryocytopoiesis 
(Katayama et al 2001), they are primarily indicated in the 
presence of signs of marrow impairment rather than to control 
hemolysis. Once again, a risk-beneﬁ  t evaluation should be 
speciﬁ  cally made for all individual cases, given that liver 
toxicity, virilizing action, and other side effects have to be 
considered; in addition, some concerns about a potential 
increase in the Budd-Chiari syndrome have been raised 
by some physicians (Parker et al 2005). A few patients in 
our series beneﬁ  ted from danazol, a non-virilizing anabolic 
steroid, given at doses of 400–600 mg/day.
Thus, given the impossibility of blocking intravascular 
hemolysis, the main strategy to control anemia was transfu-
sions. RBC transfusions are given to PNH patients according 
to their hemoglobin level, which may be highly variable even 
in the same patient; as for other anemic patients, transfusions 
should be administered to maintain hemoglobin level above 
8 gm/dL. Transfusions transiently improve anemia-related 
symptoms; however, refractoriness to transfusion may 
develop, and is considered a severe complication requiring 
more aggressive treatment − namely stem cell transplanta-
tion. In contrast to other transfusion-dependent patients, 
those with PNH have a low risk of iron overload, given the 
massive iron loss due to hemoglobinuria and hemosiderin-
uria. Thus, strategies for iron chelation are not necessary; in 
fact these patients may sometimes even require iron supple-
mentation to sustain the compensatory erythropoiesis (Rosse 
1982). Similarly, vitamin B12 and folate supplementation 
are usually indicated to sustain the enhanced erythropoiesis 
(Rosse 1982); furthermore, endogenous erythropoiesis may 
also be increased by recombinant erythropoietin, mostly 
in cases with inadequate production (Stebler et al 1990; 
Bourantas 1994; McMullin et al 1996). Paradoxically, all 
these strategies, including iron replacement, may lead to 
increased hemolysis as a result of increased PNH hemato-
poiesis, contrary to what is seen following suppression of 
erythropoiesis by transfusions.
Management of thrombophilia
The management of the propensity to develop thrombosis 
is a hot issue in PNH, given that this complication repre-
sents the ﬁ  rst cause of death. Unfortunately, there are no 
controlled prospective clinical trials on primary and second-
ary thrombosis prophylaxis, nor on acute treatment of the 
event. The issue of primary prophylaxis is controversial, and 
no consensus exists; some physicians advocate the use of 
warfarin for all newly diagnosed PNH patients, while others 
do not use any prophylaxis. Both approaches are reasonable, 
given the unpredictability of thromboembolic events and the 
lack of evidence supporting any of these strategies; possible 
beneﬁ  ts are counterbalanced by the risk of hemorrhage 
from warfarin therapy, which may be considerable in PNH 
patients with low platelet count. With the recent attempt to 
identify patients at higher risk of thrombosis, a reasonable 
compromise may be the adoption of prophylaxis for patients Biologics: Targets & Therapy 2008:2(2) 214
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with WBC PNH clones larger than 50%, or those with 
additional genetic risk for thrombosis, including ethnicity. 
Using such and approach, Hall and colleagues (Hall et al 
2003) demonstrated a very low incidence of thromboembolic 
events compared with historical controls; however, these 
data need to be conﬁ  rmed in larger series and possibly in 
prospective randomized trials that include alternative, more 
manageable, agents such as antiplatelet drugs or the new 
thrombin inhibitors.
The opinion on secondary prophylaxis is less controver-
sial, with a general agreement that all PNH patients experi-
encing any thromboembolic event should remain life-long on 
anticoagulants; however, even in this setting, no consensus 
exists on the best strategy. Low-molecular-weight heparin, 
as well as warfarin at different therapeutic ranges, are both 
utilized, with some physicians even considering the addition 
of anti-platelet agents. However, despite this extended pro-
phylaxis, recurrence of thrombosis (either as new events or 
progression of the existing ones) is frequent and affects the 
survival of PNH patients (Audebert et al 2005). Moreover, 
life-threatening hemorrhagic events are quite frequent in this 
cohort of patients, mostly when concomitant thrombocyto-
penia is present (Hall et al 2003; Moyo et al 2004).
Finally, the management of an acute thromboembolic 
disease may require an intensive therapy similar to that for 
myocardial infarct; ﬁ  brinolytic therapies using tissue plas-
minogen activator have been exploited, showing efﬁ  cient 
clearance of the thrombus in individual cases (McCullin et al 
1994; Hauser et al 2003).
Management of marrow failure
The management of marrow failure in PNH patients is 
the same as that for AA patients. Indeed, in addition to 
supportive strategies such as anti-infectious, anti-throm-
botic, and anti-hemorrhagic prophylaxis and/or treatment, 
etiologic therapies can also be attempted. According to the 
pathogenic mechanisms and the dual hypothesis described 
above, an immune-mediated inhibition of hematopoiesis 
is postulated in PNH, similar to that demonstrated in AA. 
Thus, immunosuppressive strategies have been reasonably 
attempted in PNH patients, using regimens with antilym-
phocyte or antithymocyte globulin associated with high dose 
prednisone and cyclosporin A, as those recommended in AA 
(Tichelli et al 1992); the results have been quite variable 
(Sanchez-Valle et al 1993), even if extensive studies are 
still lacking. Newer immunosuppressive agents such as the 
anti-CD52 monoclonal antibody alemtuzumab may be an 
alternative candidate as immunosuppressant; in this setting, 
there is no concern about the potential risk of selecting for 
PNH hematopoiesis, given that the GPI-linked CD52 is not 
expressed on HSCs.
So, after 3 decades of efforts the conclusion is that no 
therapy adequate to the patients’ medical needs had been 
developed, and most patients had to face every day the 
symptoms of their disease.
Curative strategies
The only curative approach for PNH is allogeneic hemato-
poietic stem cell transplantation (SCT); alternative strategies 
include cell therapy (insertion of molecules on the outer 
surface of blood cells) (Hill et al 2006) and gene therapy 
(insertion of a functional PIG-A gene in early hematopoietic 
progenitors), but all experimental efforts have so far been 
unfruitful and seem to be far away from clinical applications. 
In addition, if the escape theory is correct, the latter approach 
may not result in clinical beneﬁ  t in PNH, since a repair of the 
damaged cell should result in cell destruction, as is believed 
to occur for normal hematopoiesis in PNH patients.
SCT has been exploited since the late 1980s, with very 
positive long-term results; however, SCT is burdened by 
signiﬁ  cant early transplant-related mortality. Most reports 
in the literature refer to single cases or small series from 
single institutions (Bemba et al 1999; Saso et al 1999; Raiola 
et al 2000), while large prospective studies are lacking. An 
overview has been recently published by Parker et al (Parker 
et al 2005), who collected data from 67 patients transplanted 
from different types of donors (syngeneic, sibling, or HLA-
identical unrelated) and using different types of conditioning 
(myeloablative or reduced intensity). Data from the entire 
group showed a 75% long-term survival, which is higher 
than that reported in a majority of individual series, likely as 
a result of a reporting bias. A recent survey from the Italian 
Transplant Group (GITMO) on 23 PNH patients transplanted 
between 1988 and 2006 showed a 6-month treatment-related 
mortality of 26% and an overall survival of 70%, with a 
median follow-up of 107 months (Santarone et al 2008). 
A similar retrospective study is currently ongoing within 
the European Blood and Marrow Transplantation (EBMT) 
group, and promises to provide useful information for evi-
dence-based decision making; preliminary results conﬁ  rm 
an overall survival in the range of 55%–65%, with older age 
and acute GvHD signiﬁ  cantly affecting the outcome, and 
apparently comparable results between sibling and unrelated 
transplants.
Given these results, guidelines for SCT in PNH are 
hard to deﬁ  ne; the procedure should be restricted to young Biologics: Targets & Therapy 2008:2(2) 215
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patients with a suitable HLA matched donor, even if the 
improvement in transplant procedures may extend SCT 
even to older recipients, once the indication is established. A 
clear indication may be an underlying bone marrow failure 
unresponsive to immunosuppression; thrombosis and refrac-
toriness to transfusion may be additional indications, even if 
they should be re-evaluated in the present era of biological 
agents, namely eculizumab. Speciﬁ  c procedures to achieve 
the best outcome will, we hope, result from the ongoing 
retrospective and prospective studies, mostly investigating 
whether the new reduced-intensity conditioning regimens 
may further reduce transplant-related mortality as well as 
long-term complications.
Management: the eculizumab era
Mode of action and pharmacokinetics
Eculizumab (h5G1.1-mAb, Soliris®, Alexion Pharmaceuti-
cals) is a humanized monoclonal antibody (mAb) (Figure 4) 
derived from the murine anti-human C5 mAb (Rother 
et al 2007). It speciﬁ  cally binds the terminal complement 
fraction 5, thereby inhibiting the cleavage to C5a and C5b 
(Figure 5) (Matis and Rollins 1995), thus blocking the 
formation of the membrane attack complex (MAC), which 
is the terminal effector mechanism leading to intravascular 
hemolysis of PNH RBCs. In addition, eculizumab prevents 
the release of pro-inﬂ  ammatory mediators resulting from 
C5a cleavage. The blockade of the complement cascade 
at the level of C5 does not affect early complement com-
ponents (such as C3 and its cleavage products), preserv-
ing pivotal functions leading to clearance of immune 
complexes and microorganisms (Matis and Rollins 1995). 
Eculizumab was initially investigated in patients suffer-
ing from rheumatoid arthritis, psoriasis, systemic lupus 
erythematosus, dermatomyositis, and idiopathic membra-
nous glomerulopathy; however, PNH appeared the best 
candidate disease to beneﬁ  t from eculizumab treatment. 
In fact, the lack of CD59 on red cell membranes accounts 
for uncontrolled C5b-9 (MAC) assembly, ﬁ  nally resulting 
in intravascular hemolysis (Figure 3); theoretically, eculi-
zumab may compensate for the absence of CD59 blocking 
the MAC formation, thus rendering irrelevant the absence 
of CD59 on PNH RBCs (Figure 6).
At a more detailed analysis of the properties of eculizumab, 
it appears that the antibody has a human kappa light chain con-
stant region, while the heavy constant region results from the 
combination of IgG2 CH1 and IgG4 CH2 and CH3 domains; 
thus eculizumab does not activate the complement by itself. 
The speciﬁ  city for human C5 is quite stringent, as demonstrated 
by the almost total absence of species cross-reactivity. Pharma-
codynamic (PD) and pharmacokinetic (PK) proﬁ  les of eculi-
zumab have been assessed by a serum complement hemolysis 
in vitro assay and an ELISA analysis of serum concentration, 
using different dosing schedules. Hemolysis was considered 
inhibited if lysis of antibody-sensitized chicken erythrocytes 
after sample serum incubation was 20% of that with nor-
mal serum; eculizumab through levels above 35 μg/mL were 
demonstrated to saturate the C5 target and to block hemolysis 
in more than 80% of samples. Several loading doses were 
evaluated, and a ﬁ  xed 600 mg weekly dose was shown to be 
effective in achieving pharmacodynamically effective con-
centrations of 35 μg/mL; the ﬁ  xed dose was exploited after 
demonstrating that the PK proﬁ  le did not correlate with weight 
or other patient-speciﬁ  c factors. The PK proﬁ  le demonstrated 
Figure 4 Eculizumab: the molecule. The structure of the anti-complement 5 human-
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Figure 5 The complement cascade and the C5 blockade by eculizumab. Eculizumab 
blocks the cleavage of C5 to C5a and C5b; all earlier steps of the complement cascade 
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a non-linear behavior; further complex mathematical models 
describing PK parameters (ie, an equation relating the vol-
ume of the central compartment to the amount of drug in that 
compartment) yielded an estimated half-life of 271 hours, 
with the onset of steady-state concentrations predicted to be 
reached after 57 days of therapy. Eculizumab is administered 
intravenously, thus its bioavailability is 100%. The drug is 
distributed within vascular and extracellular spaces as other 
endogenous antibodies; the effects of non-C5 plasma proteins 
on eculizumab distribution have not been determined. The 
elimination of eculizumab is expected to involve uptake into 
endothelial pinocytotic vesicles containing Fc receptors and 
other mechanisms active in native antibody recycling; given its 
size, elimination through the kidneys, the liver, the lungs, and 
the gastrointestinal system is not expected (and even experi-
mentally proven for the kidneys). Based on these ﬁ  ndings, 
eculizumab therapy was designed to rapidly reach PD levels 
using an induction regimen, followed by a maintenance dosing 
schedule to avoid concentration drop below 35 μg/mL. In all 
PNH studies eculizumab has been administered as 4-weekly 
doses of 600 mg (induction regimen), followed by 900 mg 
doses every other week (maintenance regimen), starting 1 week 
after induction (week 5); this is the standard schedule, recently 
approved by the FDA for the treatment of PNH.
Efﬁ  cacy
Eculizumab has been evaluated in a number of clinical 
trials enrolling PNH patients with hemolytic disease and 
transfusion dependence; overall, almost 200 patients have 
been enrolled. The ﬁ  rst open-label pilot study included 
11 patients and provided the initial evidence of efﬁ  cacy, 
proving the principle that blocking C5 may reduce hemolysis 
in PNH patients (Hillmen et al 2004; Hill et al 2005a). Then, 
the deﬁ  nitive evidence of efﬁ  cacy was provided by 2 large 
multi-center trials, the TRIUMPH and the SHEPHERD 
studies.
The TRIUMPH study (Hillmen et al 2006) was a double-
blind, placebo-controlled study which randomized 87 patients 
to receive intravenously either placebo or eculizumab at 
4-weekly doses of 600 mg (induction period), followed by 
900 mg every other week (maintenance period). Inclusion 
criteria were transfusion-dependent PNH patients with no 
clinically signiﬁ  cant marrow failure (no neutropenia or 
thrombocytopenia); the treatment period was 6 months. 
Eculizumab was able to inhibit in vivo the intravascular 
hemolysis of PNH patients, as confirmed by rapid and 
sustained reduction of LDH levels, measured as area under 
the curve, in patients receiving the drug compared with the 
control group. Eculizumab was more effective than placebo 
in improving anemia, with hemoglobin stabilization in 48.8% 
of patients versus 0% in the placebo group. As a result, 
51.2% of eculizumab-treated patients no longer required 
transfusions compared with 0% of those receiving placebo. 
As a group, the median number of red cell units transfused 
was 0 in the eculizumab group and 10 in the placebo group, 
globally indicating a signiﬁ  cant reduction in transfusion 
requirement; even patients who still required transfusions 
while on eculizumab showed a signiﬁ  cantly reduced need 
for transfusion than before treatment. The amelioration of 
anemia translated into a signiﬁ  cant improvement of fatigue 
and quality of life (see below).
These data were conﬁ  rmed in the subsequent SHEPHERD 
trial (Brodsky et al 2008), an open-label study designed to 
test eculizumab in a broader PNH population, which included 
patients with minimal transfusion requirement and even those 
with thrombocytopenia. This international study enrolled 
97 patients, who received a 52-week treatment; globally, the 
patients showed a signiﬁ  cant blockade of hemolysis com-
pared with the pre-treatment period, as assessed by an 87% 
reduction of LDH level. As predicted, the reduced hemolysis 
improved the condition of anemia, to the extent that 51% of 
patients did not require transfusion.
Patients originally enrolled in the TRIUMPH and the 
SHEPHERD studies joined the Extension study, an ongoing 
non-placebo-controlled trial involving patients coming from 
any of the previous eculizumab-based trials (including the 
Figure 6 The rationale for eculizumab in paroxysmal nocturnal hemoglobinuria 
(PNH). A. Normal red blood cells (RBCs) are protected from complement attack 
by CD59. B. PNH RBCs are susceptible to complement attack due to lack of CD59, 
resulting in hemolysis and consequent clinical manifestations. C. Eculizumab blocks 
the complement cascade inhibiting MAC formation; thus, even upon complement 
activation, PNH RBCs are protected from hemolysis, thus resulting in hemoglobin 
stabilization and reduction of thromboembolisms.
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initial pilot study). The Extension study was mostly designed 
to assess the effect of long-term treatment in terms of both 
efﬁ  cacy and safety; however, among the endpoints there was 
the prospective evaluation of thromboembolic events (TE) in 
comparison to that of the pre-treatment period. Such endpoint 
has been recently evaluated in an ad interim analysis, and 
data have been recently published; the analysis included 195 
patients who had been exposed to eculizumab (Hillmen et al 
2007). The TE rate in patients on eculizumab was 1.07/100 
patient-years, which represents an 87% reduction compared 
with that inferred from the pre-treatment period (7.37/100 
patient-years). Such a reduction seemed even more striking 
when the pre-treatment observation period was limited to the 
12 months before starting eculizumab. The protection from 
thrombosis conferred by eculizumab in high risk patient is 
conﬁ  rmed by data in patients on antithrombotics because of 
a previous TE event: eculizumab associated with antithrom-
botics resulted in a 0.62/100 patient-years TE rate, which is 
signiﬁ  cantly lower than that on antithrombotics alone, before 
eculizumab treatment (10.61/100 patient-years). Thus, ecu-
lizumab seems to reduce thrombosis in PNH patients, even 
in patient cohorts where common antithrombotics usually 
fail to show any efﬁ  cacy.
Globally, the clinical efﬁ  cacy of eculizumab in PNH 
patients consists of a rapid and sustained reduction of intra-
vascular hemolysis, leading to increased hemoglobin level, 
and to reduced need – or not need at all – for transfusions; 
in addition, all symptoms related to hemolysis, such as 
abdominal pain and dysphagia, completely remitted (Hill 
et al 2005b). Furthermore, a signiﬁ  cant reduction in the 
TE risk emerges, which may likely translate into increased 
life-expectancy. Such beneﬁ  ts were demonstrated to be 
maintained in long-term treatment, as no reduced efﬁ  cacy 
has been documented even in patients receiving the drug for 
3 years or longer.
Safety and tolerability
The safety proﬁ  le of eculizumab was assessed in the 4 stud-
ies involving PNH patients, as well as on 11 studies utiliz-
ing eculizumab for different indications; the cumulative 
exposure was 147.44 and 492.20 patient-years in the two 
populations, respectively. Three deaths were reported in the 
PNH studies, all considered unrelated to the investigational 
drug; fatal events were related to the underlying disease 
in 2 cases (1 cerebral vascular accident and 1 progression 
to chronic myelomonocytic leukemia) and to an unrelated 
accident in the third (cerebral herniation). The main con-
cern was a putative increased risk of infection, mostly by 
encapsulated bacteria, namely Neisseria spp. A case of 
meningitis by Neisseria meningitidis was initially described 
within the non-PNH cohort; since then, all patients exposed 
to eculizumab are vaccinated against Neisseria meningitidis 
using a polyvalent vaccine. In addition, all patients received 
a warning on meningitis and infectious symptoms, as well 
as a rescue antibiotic prescription. No case of meningitis 
has been documented among the 195 PNH patients receiv-
ing eculizumab; however, 3 patients developed a Neisseria 
meningitidis infection, with sepsis in 2 cases. None of these 
patients developed meningitis or other complications, and all 
recovered promptly as a result of early diagnosis and treat-
ment. Furthermore, at least 2 of the 3 cases seemed to be due 
to the Neisseria meningitidis groups, which are not covered 
by the prescribed vaccine. The incidence of serious adverse 
events was similar in eculizumab-treated patients and in those 
receiving the placebo within the TRIUMPH trial; further-
more, none of the serious adverse events was considered as 
possibly, probably, or deﬁ  nitely related to eculizumab. The 
overall rate of infectious events did not increase compared 
with the placebo group; however, herpes simplex and some 
other site-speciﬁ  c infections (nasopharyngitis, upper respi-
ratory tract infection, urinary tract infection, and sinusitis) 
appeared to be more frequent within the eculizumab-treated 
population. However, in all cases the intensity was mild and 
the clinical resolution prompt.
Globally, the most common adverse events were head-
ache, followed by pyrexia, nasopharyngitis, herpes simplex, 
nausea, fatigue, and myalgia; all these events were gener-
ally mild and resolved quickly. No discontinuation due to 
side effects of eculizumab was observed. There was some 
concern about possibly severe hemolysis episodes follow-
ing withdrawal or non-compliance with the eculizumab 
dosage regimen; however, there was no evidence of life-
threatening or serious hemolysis, even in the few patients 
who discontinued treatment and progressively returned to 
their pre-treatment levels of hemolysis. The occurrence of 
immunogenity was assessed, and was demonstrated to be 
very infrequent, if present at all, and without consequence 
on drug efﬁ  cacy. Treatment was discontinued in 3 patients 
due to pregnancy, as per protocol; of these, the two with 
adequate follow up gave birth to a normal baby, with no 
maternal complications.
In summary, a wide variety of data generated from studies 
of patients with PNH, supported by safety data from stud-
ies of patients diagnosed with other diseases, demonstrate 
that treatment with eculizumab is safe and well-tolerated 
for the treatment of PNH. Long-term treatment has not Biologics: Targets & Therapy 2008:2(2) 218
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demonstrated deviation from this safety proﬁ  le; however, 
anti-meningococcal vaccination and warning for symptoms 
of meningitis remain mandatory.
Patient-focused perspectives
Patient-reported outcomes were systematically assessed in all 
eculizumab-based studies (Hillmen et al 2006; Hillmen et al 
2007; Brodsky et al 2008); fatigue is a common symptom of 
PNH patients, and signiﬁ  cantly affects their quality of life. In 
addition, painful and disabling hemolysis-speciﬁ  c symptoms 
may be present, ﬁ  nally resulting in global health status and 
patient functioning impairment (Hill et al 2005b). Eculizumab 
treatment was associated with signiﬁ  cant improvement in 
fatigue, as measured by both the FACIT and the EORTC 
QLQ-C30 fatigue scales. In addition, eculizumab-treated 
patients reported a signiﬁ  cant improvement in a number of 
EORTC QLQ-C30 subscales, including global health status, 
role, social, cognitive, physical and emotional functioning, 
pain, dyspnea, and appetite loss. This unequivocally dem-
onstrated that eculizumab improves the quality of life and 
the well-being of PNH patients improving both anemia and 
anemia-related symptoms, as well as other disease-related 
symptoms. As a result, patient’s acceptance of the treatment 
is enthusiastic, even if the treatment schedule requires fre-
quent and possibly tiresome journeys and hospitalizations, 
usually in day hospital, to receive the drug.
Future directions
Eculizuamb was effective in controlling intravascular hemo-
lysis in all PNH patients, as demonstrated by their LDH 
levels, with the exception of a few patients who experienced 
breakthrough hemolysis on eculizumab with the standard 
14-day schedule. These patients usually show recurrence 
of hemolysis toward the end of the interval, ie, 1 or 2 days 
before receiving the following dose, and may be rescued by 
shortening to 12 days the interval between administrations. 
Beside this PK exception, all patients on eculizumab show 
a complete and sustained block of intravascular hemolysis; 
however, some of them do not achieve normalization of their 
hemoglobin level and show persistent high reticulocyte count 
and increased serum bilirubin in presence of a normal mar-
row function, and even after stimulation by erythropoietin 
(Hill et al 2007b). Thus, residual low-titer hemolysis can be 
suspected in most PNH patients on eculizumab (Hillmen 
et al 2004); the hemolysis may be due to pathophysiological 
mechanisms other than those so far described in PNH 
(Rosenfeld et al 1985). Based on personal ongoing investiga-
tion (Risitano et al 2006), we suggest that eculizumab may 
induce substantial changes in PNH biology, leading to the 
possible transformation of a disease with typical intravascular 
hemolysis into a new one characterized by prevalent extravas-
cular hemolysis. As discussed above, eculizumab blocks C5 
cleavage and subsequent intravascular hemolysis, but does 
not affect C3 deposition and cleavage on RBC membrane, 
which is not controlled given the absence of CD55 (Figure 3). 
Thus the accumulation of C3 allowed by the increased PNH 
RBC survival on eculizumab treatment may lead to unex-
pected extravascular hemolysis in the reticulo-endothelial 
system via complement receptors. This is conﬁ  rmed by 
preliminary data from Italian patients, showing that in vivo 
RBC survival, as assessed by 51-Cr study, remains reduced 
in PNH patients on eculizumab, who have no evidence of 
residual intravascular hemolysis (Risitano et al 2007). In 
addition, C3 coating was demonstrated by direct anti-globulin 
test (C3d only) and ﬂ  ow cytometry in all PNH patients on 
eculizumab; these harbor a characteristic C3-positive RBC 
population with the PNH phenotype, in addition to the two 
expected populations of C3-negative phenotypically normal 
RBCs and C3-negative PNH RBCs. These ﬁ  ndings were not 
found in untreated PNH patients, who only showed the two 
latter RBC populations (Risitano et al 2007). This intriguing 
new mechanism of disease may become apparent only upon 
eculizumab treatment, and is currently under investigation 
to assess its actual importance in vivo and explore future 
clinical implications, namely possible strategies to optimize 
the clinical efﬁ  cacy of eculizumab.
Conclusion
Even if PNH is a rare condition, it represents an intriguing 
model of disease and has attracted the efforts of several 
generations of investigators in the last three decades. While 
the ’80s unraveled the GPI-anchor and the functional defect 
of the PNH clone, and the 1990s revealed the PIG-A gene 
and its role in the pathophysiology of the disease, this new 
century is finally bringing forth innovative therapeutic 
approaches. Mechanisms of disease in PNH have been 
almost completely elucidated in recent years and now, in 
the era of biological agents, have led to the development of 
targeted therapy through the terminal complement inhibitor 
eculizumab. Eculizumab showed great efﬁ  cacy in block-
ing complement-mediated intravascular hemolysis in PNH 
patients, leading to substantial improvements in anemia, 
fatigue, hemolysis-related symptoms and quality of life. 
In addition, preliminary data suggest that eculizumab may 
signiﬁ  cantly reduce the risk of thrombosis in PNH patients, 
likely as a result of controlling free hemoglobin level and Biologics: Targets & Therapy 2008:2(2) 219
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inhibiting the subsequent NO depletion. Thus, the new 
millennium of PNH starts with the ﬁ  rst treatment able to 
speciﬁ  cally control most symptoms of the disease, and likely 
reduce the risk of life-threatening complications, leading to 
a substantial change in the algorithm of the clinical man-
agement of PNH patients (Figure 7). Whether and how this 
new drug will affect the biology of PNH, possibly changing 
the paradigm of known pathogenic mechanisms, and, more 
importantly, affecting patient survival are the new challenge 
for the next few years.
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